Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances

27 Jan 2022

Abstract excerpt

BACKGROUND: Glioblastoma is one of the most devastating cancer worldwide based on its locally aggressive behavior and because it cannot be cured by current therapies. Defects in alternative splicing process are frequent in cancer. Recently, we demonstrated that dysregulation of the spliceosome is directly associated with glioma development, progression, and aggressiveness. METHODS: Different human cohorts and a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caveolin-1 and cellular processes
Share to Glioma Diagnosis and Treatment
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35086552
DOI: 10.1186/s13046-022-02241-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalancesPMID 35086552Read ↗

SF3B1 mutations in spliceosome-driven tumorigenesis: From splicing dysregulation to signaling network rewiring and therapeutic targeting.Semantic proximity Read ↗

Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategiesSemantic proximity Read ↗

Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review)Semantic proximity Read ↗

Current clinical management of patients with glioblastoma.Semantic proximity Read ↗

Fibronectin Type III Domain Containing 3B as a Potential Prognostic and Therapeutic Biomarker for GlioblastomaSemantic proximity Read ↗

Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms.Semantic proximity Read ↗

Studying the connection between SF3B1 and four types of cancer by analyzing networks constructed based on published research.Semantic proximity Read ↗

SF3B1 mutations constitute a novel therapeutic target in breast cancer.Semantic proximity Read ↗

The SF3B1R625H mutation promotes prolactinoma tumor progression through aberrant splicing of DLG1.Semantic proximity Read ↗

The GD3 ganglioside promotes cell growth, plasticity and chemotherapy resistance of human glioblastoma cancer stem cellsSemantic proximity Read ↗

Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drugSemantic proximity Read ↗

Mutant SF3B1 promotes AKT- and NF-κB-driven mammary tumorigenesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.